Unity Biotechnology, Inc.: auditor change — Unity Biotechnology restates financials for warrant misclassification; net loss overstated by $15.5M in 2022

Unity Biotechnology, Inc.

Audit committee determined warrants issued Aug 2022 should be liabilities, not equity; all affected periods are being restated.
Previously reported cash, equivalents and marketable securities balances unaffected; cash runway into Q3 2025 unchanged.
Preliminary cumulative effect: understatement of other income and overstatement of net loss by $15.5M for FY2022, $2.3M for nine months ended Sep 2023.
Company expects at least one material weakness in internal control over financial reporting; controls deemed ineffective for restated periods.
Restated financials will be included in 2023 10-K; prior financials for non-reliance periods should no longer be relied upon.

item 4.02

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Unity Biotechnology, Inc. reported that prior financial statements should not be relied upon.

Action: non reliance

Exact text from the filing

As a result, the audited and unaudited financial statements for each of the Non-Reliance Periods should no longer be relied on.

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0000950170-24-034175

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.